Subscribe To
OTLK / Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
Content Topics
Outlook
Therapeutics
Present
Btig
Virtual
Biotechnology
Therapeutics
Conference
Stock
OTLK
OTLK News
By GlobeNewsWire
November 1, 2023
Outlook Therapeutics® to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology (INI) Conference
Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET more_horizontal
By GlobeNewsWire
September 21, 2023
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET Live video webcast panel presentation on Tuesday, September 26th at 1:3 more_horizontal
By InvestorPlace
August 30, 2023
Why Is Outlook Therapeutics (OTLK) Stock Down 78% Today?
Outlook Therapeutics (NASDAQ: OTLK ) stock is taking a beating on Wednesday after getting a rejection letter from the FDA. That letter has to do with more_horizontal
By Proactive Investors
August 30, 2023
Outlook Therapeutics collapses as FDA rejects application for eye drug
Outlook Therapeutics Inc (NASDAQ:OTLK) stock collapsed, losing some 70% of its value in premarket, after the drug discovery firm's potential treatment more_horizontal
By Reuters
August 30, 2023
US FDA declines to approve Outlook Therapeutics' eye disease drug
Outlook Therapeutics said on Wednesday the U.S. Food and Drug Administration declined to approve its experimental eye disease drug, in part due to man more_horizontal
By Zacks Investment Research
August 14, 2023
Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings?
Outlook Therapeutics (OTLK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season more_horizontal
By GlobeNewsWire
August 1, 2023
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
ISELIN, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA appr more_horizontal
By Seeking Alpha
June 10, 2023
Outlook Therapeutics: August PDUFA May Be A Buy With Some Caveats
OTLK is developing an ophthalmic formulation of bevacizumab. There is a logic behind this, and there's also positive data. However, certain developmen more_horizontal